Charles Schwab Investment Management Inc Eq Rx, Inc. Transaction History

Charles Schwab Investment Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	BUY	$1.66 - $2.31 $510,401 - $710,258	307,471 Added 15.85%	2,247,743 $4.99 Million
Q2 2023 Aug 09, 2023	BUY	$1.61 - $1.96 $477,134 - $580,859	296,357 Added 18.03%	1,940,272 $3.61 Million
Q1 2023 May 11, 2023	BUY	$1.8 - $2.83 $16,936 - $26,627	9,409 Added 0.58%	1,643,915 $3.19 Million
Q4 2022 Feb 13, 2023	BUY	$2.05 - $5.5 $66,053 - $177,215	32,221 Added 2.01%	1,634,506 $4.02 Million
Q3 2022 Nov 14, 2022	BUY	$0.94 - $5.99 $188,292 - $1.2 Million	200,311 Added 14.29%	1,602,285 $7.93 Million
Q2 2022 Aug 15, 2022	BUY	$3.2 - $5.69 $859,555 - $1.53 Million	268,611 Added 23.7%	1,401,974 $6.58 Million
Q1 2022 May 13, 2022	BUY	$2.8 - $7.39 $3.17 Million - $8.38 Million	1,133,363 New	1,133,363 $4.68 Million

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.